Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study

Rita Oladele¹, Folasade Ogunsola², Alani Akanmu², Katie Stocking³, David W Denning⁴, Nelesh Govender⁵

1. University of Lagos College of Medicine, Medical Microbiology & Parasitology
2. University of Lagos College of Medicine
3. University Hospital of South Manchester NHS Foundation Trust
4. The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
5. National Institute for Communicable Diseases

Abstract

Introduction: Nigeria has a large estimated burden of AIDS-related mycoses. We aimed to determine the proportion of patients with AIDS-related opportunistic fungal infections (OFIs) at an urban antiretroviral treatment (ART) centre in Nigeria.

Methods: A retrospective analysis of a cohort of ART-naïve, HIV-infected patients, assessed for ART eligibility and ART-experience at the PEPFAR outpatient clinic at Lagos University Teaching Hospital over a 12-year period (April 2004-February 2016) was conducted.

Results: During this period, 7,034 patients visited the clinic: 4,797 (68.2%) were female; 6161 patients had a recorded baseline CD4 count, and the median CD4 count was 184 cells/µl (IQR, 84-328). A baseline HIV-1 viral load (VL) was recorded for 5,908 patients; the median VL was 51,194 RNA copies/ml (IQR, 2,316-283,508) and 6,179/7046(88%) had initiated ART. Some 2,456 (34.9%) had a documented opportunistic infections, of whom 1,306 (18.6%) had an opportunistic fungal infection. The total number of OFI episodes was 1,632: oral candidiasis (n=1,473, 90.3%), oesophageal candidiasis (n=118; 8%), superficial mycoses (n=23; 1.6%), Pneumocystis pneumonia (PJP) (n=13; 0.8%), and cryptococcal meningitis(CM) (n=5; 0.4%). 113 (1.6%) were known to have died in the cohort.

Conclusion: Approximately 1 in 5 HIV-infected patients in this retrospective cohort, most of whom had initiated ART, were clinically diagnosed with an OFI. Improved access to simple accurate diagnostic tests for CM and PJP should be prioritised for this setting.

Keywords: Opportunistic fungal infections; ART Adherence; Advanced HIV disease.

DOI: https://dx.doi.org/10.4314/ahs.v20i4.9

Cite as: Oladele R, Ogunsola F, Akanmu A, Stocking K, Denning DW, Govender N. Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study. Afri Health Sci. 2020;20(4):1573-81. https://dx.doi.org/10.4314/ahs.v20i4.9

Introduction

The morbidity and mortality associated with HIV infection has reportedly decreased over the past decade, corresponding to increasing access to antiretroviral therapy (ART). None the less, around 1 in 3 people living with HIV (PLHIV) still present to care with advanced HIV disease. This proportion is higher in low and middle-income settings¹. Furthermore, a growing number of PLHIV are returning to care with advanced disease following a period of treatment interruption¹. Worldwide, AIDS-related death rose to 1.7 million in 2004 but has been on a steady decline to 770,000 as of 2018². In Nigeria, there were 94,000 AIDS deaths in 2003 which declined to 53,000 in 2018³. Notwithstanding this progress, the decline in AIDS-related death appears to have plateaued in recent years 1, which is mostly due to the persistent challenge of Advanced HIV Disease⁴.

Corresponding author:
Rita Oladele,
University of Lagos College of Medicine,
Medical Microbiology & Parasitology
Email: oladelerita@gmail.com
Globally, the proportion of people presenting with Advanced HIV Disease (AHD) has remained mostly unchanged during the past five years, although the number of people receiving ART in low- and middle-income settings has more than doubled over this period. Opportunistic infections (OIs) are the leading cause of morbidity and mortality in this population with advanced HIV disease (defined as CD4+ T-lymphocyte CD4 count <200 cells/µl or World Health Organization (WHO) clinical stage 3 or 4). An estimated 40-50% of OIs in patients with advanced HIV disease are caused by fungal pathogens, with an estimated 2 and 10 million annual cases of oropharyngeal and oesophageal candidiasis respectively in this population. Mucocutaneous and superficial fungal infections are the most common group of opportunistic fungal infections (OFIs). While these are not life-threatening, they often lead to considerable social stigma, pain, discomfort and impact on patients’ quality of life.

Cryptococcus neoformans is the most common cause of meningocencephalitis among those with advanced HIV and now accounts for about 15% of AIDS-related deaths globally. While Pneumocystis jirovecii is the commonest cause of pneumonia in patients with AIDS in many parts of the world, it is dwarfed by tuberculosis in southern Africa. Histoplasma capsulatum (parts of the Americas and Africa) and Talaromyces marneffei (South and Southeast Asia) are thermally dimorphic fungi causing disseminated infections in the HIV/AIDS population. A recent review by Adenis et al (2018) revealed that the burden of histoplasmosis is estimated to be equivalent in incidence and even higher in deaths when compared with tuberculosis among people living with HIV in Latin America. Also, Coccioidioides causes disease among patients with AIDS (Americas) and Emergomyces africanus has been recently described as a cause of disseminated OFI in southern Africa. These are all AIDS-defining OIs and are usually lethal unless diagnosed and treated early and appropriately.

Most serious OFIs demand high-level medical skills to make a diagnosis, affect all body systems and may be misdiagnosed as other diseases (e.g. tuberculosis). In addition they kill at least as many patients with AIDS comparable to tuberculosis or bacterial infections. There have been enormous advances in development of fungal diagnostics and antifungal agents over the past 20 years, but most of the world’s population (especially in low- and middle-income countries LMICs) have not yet benefited from these advances. In Nigeria, the absence of diagnostic tools and antifungal agents, plus insufficient training of healthcare staff, means that the morbidity and mortality of fungal OIs remains unacceptably high.

With the increased availability of antiretroviral treatment (ART), earlier testing and treatment for HIV, the incidence of OFIs has decreased dramatically in people living with HIV in high-income countries. In contrast, in regions with a high HIV prevalence, especially sub-Saharan Africa, there is little evidence for a substantial decrease in cases of OIs. In these settings, many patients present with advanced HIV. There have been enormous advances in development of fungal diagnostics and antifungal agents over the past 20 years, but most of the world’s population (especially in low- and middle-income countries LMICs) has not yet benefited from these advances. In countries with developed health systems, fungal OIs are usually appropriately diagnosed and treated, although many are still missed and only identified at autopsy. In Nigeria, the absence of diagnostic tools and antifungal agents, plus insufficient training of healthcare staff, means that the morbidity and mortality of fungal OIs remains unacceptably high.

There are 1,900,000 PLWHIV in Nigeria with 53,000 AIDS deaths estimated to have occurred in 2018; only 67% of PLHIV know their status, 53% are on treatment and 42% are virally suppressed. Nigeria has the 7th highest burden of tuberculosis globally; and an estimated 11.8% of Nigerians suffer from serious fungal infections annually and if Tinea capitis and recurrent vulvovaginal candidiasis are excluded, over 960,000 individuals are affected, with substantial mortality. Twenty five thousand cases of cryptococcosis are estimated to occur annually. Histoplasmosis is endemic in Africa, and literature reviews identified 124 documented cases in Nigeria (all before the advent of HIV). These infections account for significant morbidity and mortality in the AHD population. We aimed to determine the proportion of patients with clinically diagnosed AIDS-related OFIs at an urban ART centre in Nigeria with limited capacity for diagnosis of OFIs.

**Methods**

**Study design and setting**

A descriptive retrospective study was conducted over a 12-year period (April 2004-February 2016). ART-naïve,
HIV-infected adolescents and adults; who were assessed
for ART eligibility (including WHO HIV Stage 3/4 dis-
ease or CD4 cell count of 500 cells/ml) at the Pres-
ident's Emergency Plan for AIDS Relief (PEPFAR)
outpatient clinic of Lagos University Teaching Hospi-
tal (LUTH), Nigeria, were included in the study. Lagos
is a cosmopolitan city with an estimated population
of 20 million people. This clinic has medical officers,
specialist doctors, nurses, counsellors, well-staffed data
office, phlebotomists etc. Patients get admitted to the
hospital from this clinic. The study population included
HIV-seropositive patients, 15-years-old and above. The
LUTH-PEPFAR program was established in close part-
nership with the comprehensive HIV prevention, treat-
ment and care services provided by Harvard University
and Northwestern University.

Demographic and clinical data for each clinic visit were
captured in a database. APIN (Aids Prevention In-
itiative in Nigeria) laboratory services this clinic. The
laboratory provides for free HIV screening and con-
firmatory test, CD4 count, viral load, blood chemistry,
hepatitis B and C testing. A panel of laboratory tests
were performed at baseline and follow-up visits, includ-
ing CD4 counts and HIV-1 viral load (VL). Patients/
relatives pay for tests and treatment that is not covered
by theEPFAR/APIN program. Infections (outside of
Hepatitis B and C) diagnostics are not covered, and no
fungal infection is covered. It was observed that most
OIs, including OFIs, were diagnosed clinically in the
studied population. Laboratory records were accessed
from the PEPFAR clinic database. CD4 counts were
chosen from tests closest to the period of diagnosing
an OI.

Ethical statement
The research and ethics committee of LUTH, HREC:
19/12/2008a approved this retrospective record-based
study. Anonymised data only were analysed.

Definitions (As used in Centre of study to make
diagnosis)
Advanced HIV disease in this study was defined as
CD4+ T-lymphocyte CD4 count <200 cells/µl or
World Health Organization (WHO) clinical stage 3 or
4. The most recent CD4+ count (around the OI diag-
nosis) was used.

Pneumocystis jirovecii pneumonia (PJP): sympto-
matic presentation with compatible chest radiographs
and clinical response to an appropriate therapeutic reg-
imen.

Candida oesophagitis: symptomatic presentation of
dysphagia, odynophagia or retrosternal chest pain with
endoscopic evidence of lesions compatible with the di-
agnosis of oesophageal candidiasis or clinical response
to appropriate antifungal therapy.

Cryptococcal meningitis: Microscopic demonstra-
tion of Cryptococcus yeasts on India ink preparation
or isolation of the organism from cerebrospinal fluid
sample.

Oral candidiasis: symptomatic presentation of white
patches (plaques) in the mouth that could be wiped off
leaving behind red areas that may bleed slightly.

Superficial mycoses: Skin, hair or nail lesions with mi-
crobiological identification using skin/ nail/ hair mate-
rial or symptomatic relief with appropriate therapeutic
regimens.

Data analysis
The date of the earliest OI was compared to the date
of the CD4 and RNA visits. The CD4 and RNA val-
ues were taken from the date, which was closest to the
earliest OI. Patients were only considered for analysis
if their visit date was within 90 days of the earliest OI
date. If there was any patients with more than one value
from the closest date the maximum value for CD4 and
RNA was used.

Descriptive statistics were used to summarize the data
by time period, age and gender. We described categori-
cal variables using frequencies and relative frequencies.
For continuous variables, an assessment of normality
was carried out. If the variable was found to be normal-
distributed, the mean, standard deviation and range
was given. Non-normally distributed variables were
described using their median, range and interquartile
range. We compared categorical variables using the chi
square or Fisher’s exact test and continuous variables
using Student’s t test or a non-parametric equivalent. All
analyses were performed using SPSS version 22.0 (IBM
SPSS Statistics. Armonk, NY: IBM Corp.).

Results
The clinic database contained 15,098 records, each re-
cord corresponding to a clinic visit by an individual pa-
tient between the period of April 2004-February 2016.
Duplicate records were removed prior to analysis. A
total of 7,034 patients with available information were
included in the final analysis. The majority (n=4,797,
68%) of patients were female Table 1. The mean age
was 37 years (SD-10); Table 1). The mean age at diag-
nosis of HIV disease for males was 41 years, (SD-9)...
For females, the mean age was 35 years; SD-10. The
median number of visits per patient was 2, with an in-
terquartile range of 1 to 3. A baseline viral load was
recorded for 5,908 patients; the median VL was 51,194 RNA copies/ml (IQR, 2,316-283,508). Most patients (6,179/7,034; 88%) were recorded as having initiated ART in this clinic during the study period. Of 7,034 patients, 2,456 (35%) had a documented OI. The median CD4 count from the visit that was closest to the date of the earliest OI (within 90 days) was 197 (N=49, IQR 69.5-377.5). One in five patients was diagnosed as having tuberculosis (TB) over the 12-year period (n=1,381 20%), of whom 1,282 (18%) were cases of pulmonary TB and 182 (3%) were cases of extra-pulmonary TB. A small number of the patients (17) or 0.2% had HIV encephalopathy. No confirmed cases of Toxoplasma gondii encephalitis were documented. There were only 113 (1.6%) deaths recorded in the database over the study period. See table 1.

### Table 1: Patient demographics, CD4 counts and RNA measurements.

| Characteristic                          | Value† |
|-----------------------------------------|--------|
| Age (Years)                             | 37.3 (10.0) |
| Mean (Standard Deviation)               | 8      |
| Minimum                                | 78     |
| Maximum                                |        |
| Sex                                     |        |
| Male                                    | 2236 (31.8) |
| Female                                  | 4797 (68.2) |
| Age at diagnosis, split by gender (Years)|        |
| Males:                                  |        |
| Mean (Standard Deviation)               | 41.3 (9.0) |
| Minimum                                | 13     |
| Maximum                                | 69     |
| Females:                                |        |
| Mean (Standard Deviation)               | 33.0 (9.7) |
| Minimum                                | 8      |
| Maximum                                | 78     |
| ART - initiated                         | 6179 (88) |
| ART- naive                              | 855 (12) |
| CD4 Count                               |        |
| Median                                  | 184    |
| Minimum                                 | 1      |
| Maximum                                 | 1657   |
| First Quartile‡                        | 85     |
| Last Quartile‡                         | 328    |
| Last Count:                             |        |
| Median                                  | 418    |
| Minimum                                 | 1      |
| Maximum                                 | 2096   |
| First Quartile‡                        | 221    |
| Last Quartile‡                         | 612    |
| RNA Measurement (Viral load)            |        |
| First Measurement:                     |        |
| Median                                  | 51259  |
| Minimum                                 | 0      |
| Maximum                                 | 16,100,000 |
| First Quartile‡                        | 2314   |
| Last Quartile‡                         | 283617 |
| Last Measurement:                      |        |
| Median                                  | 200    |
| Minimum                                 | 0      |
| Maximum                                 | 16,100,000 |
| First Quartile‡                        | 25     |
| Last Quartile‡                         | 8597   |
| Mortality                               | 113 (1.6) |

†Unless otherwise specified, values are number of patients (%)
‡ First quartile=25th percentile; third quartile=75th percentile.
Frequency and distribution of opportunistic fungal infections

The total number of patients with an AIDS-related OFI was 1,306 (19%) see table 2. Most patients (1,197/1306) or 92%, had only one OI; 99 patients had 2 different OIs diagnosed, 6 patients had 3 different OIs and 4 patients had five OIs (this is not including multiple diagnoses of the same OI). Of the 1,306 patients, 1,284 (98%) had an episode of oral candidiasis; with 1,473 episodes documented for these 1,284 patients. One hundred and ten (8%) patients had oesophageal candidiasis with 118 episodes diagnosed in total. Thirteen (1.0%) patients were diagnosed with single episodes of PJP. Only 5 (0.4%) patients had cryptococcal meningitis diagnosed. Twenty-one (1.6%) patients were diagnosed with superficial (skin and nail) mycoses (Table 2), with 23 incidences in total. When considering multiple diagnoses of the same OFI, there were 1,632 episodes among 1,306 patients. Two hundred and forty patients had between 2 and 7 episodes of OIs, with the remaining 1,066 patients having 1 OI. The majority (90%) of the 1,632 OI episodes were Candida oral infections. Around 7% (118) of the OIs were cases of oesophageal candidiasis. PJP, superficial mycoses and cryptococcal meningitis each made up less than 1.5% of the total number of OIs reported (Table 2).

Table 2: AIDS-related fungal opportunistic infections

| Infection                                      | Number | Percent of total population | Percent of those with AIDS-related fungal opportunistic infections |
|-----------------------------------------------|--------|----------------------------|-------------------------------------------------------------------|
| Any AIDS-related fungal opportunistic infection | 1306   | 18.6                       | -                                                                 |
| Oral candidiasis                              | 1284   | 18.3                       | 98.3                                                             |
| Oesophageal candidiasis                       | 110    | 1.6                        | 8.4                                                              |
| Pneumocystis pneumonia                        | 13     | 0.2                        | 1.0                                                              |
| Cryptococcal meningitis                       | 5      | 0.1                        | 0.4                                                              |
| Superficial mycoses                           | 21     | 0.3                        | 1.6                                                              |

There was no significant difference between the age of patients who had any OI and those who did not have an OI (38, SD 11 vs 37, SD 10; p=0.30), table 3. Male patients were significantly more likely to have an OI than female patients; 22.3% (498/2236) of males had an OI compared to 16.8% (807/4797) of females (p<0.001). See table 3.

Table 3: Relationship between fungal opportunistic infections and age and gender

| Infection                                      | Number | Number (%) | Mean age (SD), range |
|-----------------------------------------------|--------|------------|---------------------|
| Any AIDS-related fungal opportunistic infection | 1306   | 498/1305 (38.2%) | 38.1 (10.7), 11-68 |
| Oral candidiasis                              | 1284   | 489/1283 (38.1%) | 37.9 (10.5), 11-68 |
| Oesophageal candidiasis                       | 110    | 46 (41.8%) | 39.2 (9.0), 27-60 |
| Pneumocystis pneumonia                        | 13     | 3 (23.1%) | 58.5 (9.2), 52-65 |
| Cryptococcal meningitis                       | 5      | 0         | -                   |
| Superficial mycoses                           | 21     | 9 (42.9%) | 38.6 (14.8), 13-55 |

PCP: Pneumocystis pneumonia
Relationship with CD4 count
There was a statistically significant difference in the CD4 counts at both the first visit of a patient and at the last visit of a patient (both $p<0.001$). At their first visit, patients who had an OI during the study period had a lower CD4 count compared to those who did not have an OI during the study period (with OI: median 112; IQR 46-242 vs without OI: median 199; IQR 99-343). There appeared to be a slightly larger difference in CD4 count at a patient’s last visit between those who did and those who did not have an OI during the study period (with OI: median 248; IQR 82-474 vs without OI: median 442; IQR 253-628).

Trends of opportunistic fungal infections from 2004 to 2016
Among cases of OFIs with a recorded date of diagnosis (1,403 out of 1,632), most cases occurred in 2015 (185 cases) followed by 2014 (166 cases); 2005 and 2006 (164 cases each). The year 2004 had the lowest recorded cases (11) followed by 2012 (24 cases) and 2016 (33 cases). Figure 1

Discussion
In 2013, of all persons living with HIV globally, 9% lived in Nigeria. OIs are associated with reversible increases in circulating viral load which could lead to accelerated HIV progression or increased transmission of HIV. This is contrary to the Millennium Development Goal; which aimed at halting and beginning to reverse the HIV epidemic by 2015. Sixty-eight percent of the studied population was female. This is in keeping with reports from other Nigerian studies, which revealed 59 – 66%. Approximately a third of the studied population in this study had an OI; higher than the 22% reported from Eastern Nigeria and 26% from Central Nigeria but lower than 69% reported from North Central Nigeria. The data from North Central Nigeria was collected prior to the HAART (highly active antiretroviral therapy) era. However our data spanned both pre-HAART and HAART eras. A recent Uganda study reported 291,168 cases among 108,619 patients over a 12-year period.
Approximately 1 in 5 HIV-infected patients in this retrospective study, most of whom had initiated ART, were clinically diagnosed with a fungal OI. The median CD4 count of patients was 197 cells/mm³ and we found that there was a statistically significant difference in the CD4 counts at both the first visit and the last visit of a patient (both p<0.001). There is extensive evidence that low baseline CD4 cell count and low CD4 cell counts during ART are major risk factors for OIs. Our finding is comparable to that of a Bahraini study, which found that the CD4 count was significantly lower in HIV-infected patients with associated infections compared with those without. Our study also revealed that males were significantly more likely to have an OI than females which is consistent with a South African study that found men were twice more likely than women to present with advanced HIV disease. A possible explanation for this might be the differences in health seeking behavior between men and women. Another possible explanation might be that women are more likely to be diagnosed early with HIV because of the screening policy for pregnant women (the highest prevalence is in the reproductive age group) and thus women are more likely to start ART earlier. Men tend to present late to care and often with advanced HIV infection; owing to stigma, socio-cultural and religious beliefs.

All OIs do not have the same prognosis. While some are life-threatening; oral and oesophageal candidiasis lowers the quality of life of people living with HIV/AIDS and interfere with drug adherence and nutritional intake. Candidiasis accounted for majority of clinically diagnosed cases of fungal OIs in this study, consistent with other reports.

A South African post mortem study on the cause of death in HIV-infected patients within the first months of ART revealed that systemic fungal OIs occurred in 21% of cases. Very few systemic opportunistic fungal infections were diagnosed in the present study. Only 5 cases of cryptococcal meningitis were diagnosed over a 12-year period. This is interesting; because in the same centre, a recent study demonstrated a prevalence of 9% of cryptococcal antigenemia. Also in the year 2018, three cases of cryptococcal meningitis were diagnosed, this was attributed to increased awareness by clinicians as a result of a training conducted by the Medical Mycology Society of Nigeria, and also due to availability of the diagnostic point of care kit in our laboratory. Meanwhile, a study from North Central Nigeria had reported an incidence of 36% cryptococcal meningitis in hospitalised HIV-infected patients presenting with neurological symptoms. Another study from the same centre on hospitalised HIV-infected patients, demonstrated that cryptococcal meningitis accounted for 8.8% of all OIs with a 12% case-fatality ratio. PJP accounted for 1% of all AIDS-related mycotic infections in the present study, this is lower than 13% reported from a study in Western Nigeria. While diagnosis in the index study was made clinically; in the study cited above, PJP was diagnosed using a PCR assay. One of the pressing challenges in making diagnosis of PJP in our setting is the lack of awareness of the fact that simple microscopy (though not very sensitive) can be used in making a diagnosis. Another challenge is the lack of skilled personnel and infrastructure to make the diagnosis. Capacity building and awareness is urgently needed, especially given the fact that a vulnerable group (young children) is at risk.

The distribution and pattern of fungal OIs (OFIs) in the studied population did not reveal any significant change in trend over the years. In the early years of HAART (2005-2009); there appears to be a slight and steady decrease in reporting of OFIs (mainly mucocutaneous candidiasis). However, the rates subsequently picked up in 2013 with the highest incidence in 2015. We are not too sure if this is due to better reporting modalities, improved clinical diagnostic acumen, better ‘retention in care’ or virological failure. Fast, accurate diagnosis is essential to reduce deaths from AIDS. GAFIT modelling suggests that making the key diagnostic tests available for only 60% of needy patients, with treatments, could save over a million lives in the next 5 years.

There is a dire need to improve access to essential diagnostics for these OFIs in Nigeria. Strategies will include training and retraining of healthcare workers managing these patients. Advocacy is also required to help improve access to essential diagnostics and making them affordable, especially in our setting, where patients pay for the services. Interestingly, we saw a very low (<2%) overall OFI-related mortality rate over the 12-year period. Possible explanations of this observation include poor retention to HIV care, loss to follow-up or poor documentation of death out of healthcare facilities.

Limitations
Lack of diagnostics and skilled personnel to make appropriate diagnosis, so our findings will not reflect the true burden of disease. Most of the diagnoses were made clinically. Hospitalised HIV-infected patients in
LUTH were not captured in this data. Fluidity of patient movements between different ART centres affects retention in care. However, this is one of the largest retrospective studies from Nigeria and could form the basis for further surveillance programs.

OFIs remain a significant cause of morbidity and mortality in the HIV-infected population. While superficial fungal infections (skin and nail) in most patients with HIV infection follow a normal pattern, atypical presentations and more severe forms are common in patients with AIDS. Diagnosis of AIDS-defining invasive OFIs such as cryptococcal meningitis has been made cheaper, easier and quicker using the CrAg LFA, which has excellent diagnostic accuracy in serum, plasma and cerebrospinal fluid. Despite an estimated cost of just $4 per test, no centre in Nigeria, a high HIV burden country with a PEPFAR/APIN funded ART program performs this test in routine clinical practice. PJP diagnosis has also been made faster and easier with PCR and beta D glucan assays. However these tests are neither presently accessible nor affordable in Nigeria.

Conclusion
This study highlights the lack of diagnostics for serious fungal infections, which are a significant cause of morbidity in a high HIV burden country. There is dire need for improved access to simple diagnostic tests for AIDS-defining fungal OIs such as CM, PJP and this should be prioritised for such settings. Fast, accurate diagnosis is essential to reduce deaths from AIDS and achieve the 90-90-90 sustainable development goals by 2030.

Competing interests
None of the authors have any conflicting interest to declare

Authors’ contributions
All authors contributed to the conceptualization, data analysis and writing of the manuscript.

List of abbreviations
AIDS Acquired immunodeficiency syndrome
ART Antiretroviral therapy
CM Cryptococcal meningitis
GAFFI Global Action Fund for Fungal Infections
HIV Human immunodeficiency virus
LMICs Low- and middle-income countries
OFI Opportunistic fungal infection
OI Opportunistic infection
PJP Pneumocystis pneumonia

PEPFAR President's Emergency Plan for AIDS Relief
UNAIDS Joint United Nations Programme on HIV/AIDS
WHO World Health Organisation

References
1 World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017.
2 UNAIDS. UNAID info. UNAIDS info. Online, 2019. https://aidsinfo.unaids.org/.
3 Federal Ministry of Health, Nigeria. HIV Health Sector Annual Report. Abuja: Federal Ministry of Health, 2018.
4 Calmy A., Ford N, and Meintjes G. The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy. Clinical Infections Diseases. April 2018, Vol. Volume 66, Issue suppl_2, pp. S103–S105.
5 Benson CA, Brooks JT, Holmes KK, et al. Guidelines for prevention and treatment opportunistic infections in HIV-infected adults and adolescents; recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1–207 PubMed.
6 Palella Jr FJ, Baker RK, Moorman AC, et al, HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006 Sep 1;43(1):27-34.
7 Buchacz K, Baker RK, Moorman AC, et al, Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDs 2008; 22:1345–1354 PubMed.
8 Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. The Lancet Infectious Diseases. 2017 Jul 31.
9 Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: Fungal infections in HIV/AIDS. Trends Microbiol 2014; 22:120–127.
10 Brown GD, Denning DW, Gow NAR, et al. Hidden Killers: Human Fungal Infections. Sci Transl Med 2012; 4.
11 Adenis AA, Valdes A, Cropet C, McCotter OZ, Derrado G, Couppie P, Chiller T, Nacher M. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. The Lancet Infectious Diseases. 2018 Oct 1;18(10):1150-9.
12 Schwartz IS, Kenyon C, Feng P, et al. 50 Years of
Emmonsia Disease in Humans: The Dramatic Emergence of a Cluster of Novel Fungal Pathogens. *PLoS Pathog* 2015; 11:1–8.WHO.

13 Global Tuberculosis Report. s.l. : WHO, 2019.

14 Oladele RO, Denning DW. Burden of serious fungal infection in Nigeria. *West Afr J Med*. 2014 Apr;33(2):107-14.

15 Rajasingham R, Smith R., Park B., Jarvis J., Govennder N., Chiller T., Denning D., Loyse A., Boulware D. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis*. Aug 2017, Vol. 17, 8, pp. 873-881.

16 Oladele R., Ayanlowo O., Richardson M., Denning D. Histoplasmosis in Africa: An emerging or a neglected disease? *PLOS Neglected Tropical Disease*. January 18, 2018.

17 Awofala AA, Ogundele OE. HIV epidemiology in Nigeria. *Sandi J Biol Sci*. 2016; 25 (4): 697-703

18 Nathan Y. Shehu , Comfort A. Daniyam Oche O. et al. Pattern of opportunistic infections in HIV Patients who fail first line antiretroviral therapy in Jos, Nigeria. *Highl Med Res J* 2014; 14:103–106 PubMed.

19 O Iroezindu MO, Ofondu EO, Hausler H et al. Prevalence and Risk Factors for Opportunistic Infections in HIV Patients Receiving Antiretroviral Therapy in a Resource-Limited Setting in Nigeria. *J AIDS Clin Res* 2013; 3:002.

20 Salami AK, Olatunji PO, Oluboyo PO. Spectrum and prognostic significance of opportunistic diseases in HIV/AIDS patients in Ilorin, Nigeria. *West Afr. J. Med.* 2006; 25:52–56 PubMed.

21 Rubaihayo J, Tumwesigye NM, Konde-Lule J, et al. Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda. *BMC Res Notes* 2016; 9:501.

22 Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. *Pediatrics* 2007; 120:100–9.

23 Granich R, Gupta S, Hersh B, et al. Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990–2013. *PLoS One* 2015; 10:e0131353.

24 Saeed NK, Farid E, Jamsheer AE. Prevalence of opportunistic infections in HIV-positive patients in Bahrain: a four-year review (2009-2013). *The J Inf Dev Count*, 2015; 9:01: 060-069

25 Carmona, S., Bor, J., Nattey, C., et al. Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa’s National HIV Program: Data From a Nationwide Laboratory Cohort. *Clin Infect Dis* 2018; 66(suppl_2), pp.S111-S117.

26 Agaba PA, Digin E, Makai R, et al. Clinical characteristics and predictors of mortality in hospitalized HIV-infected Nigerians. *J Infect Dev Ctries* 2011; 5:377–382

27 Iroezindu M. Disparities in the magnitude of human immunodeficiency virus-related opportunistic infections between high and low/middle-income countries: Is highly active antiretroviral therapy changing the trend? *Ann Med Health Sci Res* 2016; 6:4.

28 Wong EB, Omar T, Setlhako GJ, et al. Causes of Death on Antiretroviral Therapy: A Post-Mortem Study from South Africa. *PLoS One* 2012; 7:e47542.

29 Oladele RO, Akamu AS, Nwosu AO, et al. Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. *Open forum Infect Dis* 2016; 3:ofw055.

30 Gomerep S., Idoko J., Ladep N., et al. Frequency of Cryptococcal Meningitis in HIV-1 Infected Patients in North Central Nigeria. *Niger J Med* 2010; 19. doi:10.4314/njm.v19i4.61963

31 Alli OAT, Ogbolu DO, Ademola O, Oyenike MA. Molecular detection of Pneumocystis jirovecii in patients with respiratory tract infections. *N Am J Med Sci* 2012; 4:479.

32 GAFFI consensus document 2018. https://www.gaffi.org/consensus-on-essential-diagnostics-for-advanced-aids-and-fungal-diseases/